Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

(2009) Daniel D. Karp et al.   JOURNAL OF CLINICAL ONCOLOGY

Igf1r as a therapeutic target in a mouse model of basal-like breast cancer

(2009) A. Klinakis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development of monoclonal antibodies for the treatment of colorectal cancer

(2008) S. Goodin   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors

(2008) E. Buck et al.   CANCER RESEARCH

Addiction to Elevated Insulin-like Growth Factor I Receptor and Initial Modulation of the AKT Pathway Define the Responsiveness of Rhabdomyosarcoma to the Targeting Antibody

(2008) L. Cao et al.   CANCER RESEARCH

Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival

(2008) J. H. Law et al.   CANCER RESEARCH

The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors

(2008) F. Huang et al.   CANCER RESEARCH

The Type 1 Insulin-Like Growth Factor Receptor Pathway

(2008) M. M. Chitnis et al.   CLINICAL CANCER RESEARCH

Targeting insulin and insulin-like growth factor signalling in oncology

(2008) Michael Pollak   CURRENT OPINION IN PHARMACOLOGY

Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer

(2008) John SP Yuen et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma

(2008) Martha Q. Lacy et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting Polo-Like Kinase: Learning Too Little Too Late?

(2008) David Olmos et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

(2008) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer

(2008) Brian M. Wolpin et al.   JOURNAL OF CLINICAL ONCOLOGY

IGF-1 Receptor Inhibitors in Clinical Trials—Early Lessons

(2008) S. John Weroha et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis

(2008) Jing Ma et al.   LANCET ONCOLOGY

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials

(2008) J. Rodon et al.   MOLECULAR CANCER THERAPEUTICS

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors

(2008) C. Tarn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Insulin receptor expression by human prostate cancers

(2008) Michael E. Cox et al.   PROSTATE

Just Say Die

(2007) Scott R. Berry   JOURNAL OF CLINICAL ONCOLOGY